Up-regulation of IGF Binding Protein-3 Inhibits Colonic Inflammatory Response

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2018 Mar 25

PMID 29573252

Citations 5

Authors

Soon Chul Kim

Pyoung Han Hwang

Affiliations

Soon will be listed here.

Abstract

Background: The aggravating factors still remained unclear in inflammatory bowel disease (IBD). Despite many different therapeutic approaches, many patients do not respond to the therapy. The anti-inflammatory effect of insulin-like growth factor-binding protein-3 (IGFBP-3) was suggested because of its capability of nuclear factor-κB (NF-κB) signaling inhibition. Therefore, we hypothesized that the up-regulation of IGFBP-3 would inhibit an inflammatory process.

Methods: Lipopolysaccharides (LPS) treated intestinal epithelial cell 6 (IEC-6) and dextran sodium sulfate (DSS) induced colitis mice were used as colitis models. Exogenous IGFBP-3 expression was accomplished using the adenoviral vector system expressing IGFBP-3 (Ad/IGFBP-3). The inflammatory responses and relevant cellular responses in IEC-6 cells influenced by IGFBP-3 expression were evaluated by western blotting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and reactive oxygen species (ROS) measurement. The severity of colitis was evaluated with the colon tissues of DSS-induced mouse model.

Results: We found that the IGFBP-3 expression reduced the production of inflammatory cytokines (cyclooxygenase-2, interleukin-1β, tumor necrosis factor-α) and ROS formation. IGFBP-3 expression also induced cell viability and inhibited NF-κB activation. In line with this data, the severity of DSS-induced mouse colitis was greatly ameliorated by the treatment of IGFBP-3 expressing adenoviral particles characterized with less weight loss and preserved colon length compared with the mice treated with DSS alone. The histopathology of the colon showed the reducing signs of colitis in Ad/IGFBP-3 treated DSS-mice group.

Conclusion: Therefore, our data suggest that Ad/IGFBP-3 up-regulation reduces colonic inflammatory response as a novel therapeutic protocol for IBD.

Citing Articles

Expression and pathogenesis of insulin-like growth factor-1 and insulin-like growth factor binding protein 3 in a mouse model of ulcerative colitis.

Wang W, Sun X, Wang A, Lu Y, Han Y, Zhao J Heliyon. 2024; 10(15):e34920.

PMID: 39166081 PMC: 11333886. DOI: 10.1016/j.heliyon.2024.e34920.

Nematode-Induced Growth Factors Related to Angiogenesis in Autoimmune Disease Attenuation.

Maruszewska-Cheruiyot M, Krawczak-Wojcik K, Michniowska M, Stear M, Machcinska M, Doligalska M Life (Basel). 2023; 13(2).

PMID: 36836678 PMC: 9959133. DOI: 10.3390/life13020321.

MicroRNA-205-5p plays a suppressive role in the high-fat diet-induced atrial fibrosis through regulation of the EHMT2/IGFBP3 axis.

Xiao Z, Xie Y, Huang F, Yang J, Liu X, Lin X Genes Nutr. 2022; 17(1):11.

PMID: 35858845 PMC: 9297569. DOI: 10.1186/s12263-022-00712-z.

IGFBP-3 Mediates Metabolic Homeostasis During Hyperosmolar Stress in the Corneal Epithelium.

Bogdan E, Stuard W, Titone R, Robertson D Invest Ophthalmol Vis Sci. 2021; 62(7):11.

PMID: 34100890 PMC: 8196413. DOI: 10.1167/iovs.62.7.11.

Glycyrrhizin protects IGFBP-3 knockout mice from retinal damage.

Liu L, Jiang Y, Steinle J Cytokine. 2019; 125:154856.

PMID: 31526985 PMC: 6875639. DOI: 10.1016/j.cyto.2019.154856.

References

Neurath M, Fuss I, Schurmann G, Pettersson S, Arnold K, Strober W . Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci. 1999; 859:149-59. DOI: 10.1111/j.1749-6632.1998.tb11119.x. View

Podolsky D . Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-29. DOI: 10.1056/NEJMra020831. View

Plevy S, Landers C, Prehn J, Carramanzana N, Deem R, Shealy D . A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1998; 159(12):6276-82. View

Firth S, Ganeshprasad U, Poronnik P, Cook D, BAXTER R . Adenoviral-mediated expression of human insulin-like growth factor-binding protein-3. Protein Expr Purif. 1999; 16(1):202-11. DOI: 10.1006/prep.1999.1075. View

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132(3):863-73. DOI: 10.1053/j.gastro.2006.12.003. View

Lee H, Chun K, Liu B, Wiehle S, Cristiano R, Hong W . Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 2002; 62(12):3530-7. View

Benchimol E, Seow C, Steinhart A, Griffiths A . Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (2):CD006792. PMC: 6718222. DOI: 10.1002/14651858.CD006792.pub2. View

Murthy S, Cooper H, Shim H, Shah R, Ibrahim S, Sedergran D . Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993; 38(9):1722-34. DOI: 10.1007/BF01303184. View

van den Brink G, Ten Kate F, Ponsioen C, Rive M, Tytgat G, van Deventer S . Expression and activation of NF-kappa B in the antrum of the human stomach. J Immunol. 2000; 164(6):3353-9. DOI: 10.4049/jimmunol.164.6.3353. View

10.

Sawczenko A, Ballinger A, Savage M, Sanderson I . Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics. 2006; 118(1):124-9. DOI: 10.1542/peds.2005-2931. View

11.

Lee K, Ma L, Yan X, Liu B, Zhang X, Cohen P . Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem. 2005; 280(17):16942-8. DOI: 10.1074/jbc.M412757200. View

12.

He T, Zhou S, DA COSTA L, Yu J, Kinzler K, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95(5):2509-14. PMC: 19394. DOI: 10.1073/pnas.95.5.2509. View

13.

Rao A, Standing J, Naik S, Savage M, Sanderson I . Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study. BMJ Open. 2013; 3(5). PMC: 3664353. DOI: 10.1136/bmjopen-2013-002737. View

14.

Cho J . The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008; 8(6):458-66. DOI: 10.1038/nri2340. View

15.

Eivindson M, Gronbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A . The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. Scand J Gastroenterol. 2007; 42(4):464-70. DOI: 10.1080/00365520601010115. View

16.

Katsanos K, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos E . Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res. 2002; 11(6):364-7. DOI: 10.1054/ghir.2001.0248. View

17.

Bento A, Marcon R, Dutra R, Claudino R, Cola M, Leite D . β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am J Pathol. 2011; 178(3):1153-66. PMC: 3070571. DOI: 10.1016/j.ajpath.2010.11.052. View

18.

Lee H, Woo S, Koh H, Ka S, Zhou L, Jang K . Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis Rheumatol. 2014; 66(4):863-73. DOI: 10.1002/art.38303. View

19.

Jones J, Clemmons D . Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16(1):3-34. DOI: 10.1210/edrv-16-1-3. View

20.

Kim M, Kim S, Arunachalam S, Hwang P, Yi H, Nam S . c-myb stimulates cell growth by regulation of insulin-like growth factor (IGF) and IGF-binding protein-3 in K562 leukemia cells. Biochem Biophys Res Commun. 2009; 385(1):38-43. DOI: 10.1016/j.bbrc.2009.05.018. View